{"title":"烟酸缓释(ER)/辛伐他汀(Simcor®):用于脂质调节的指南。","authors":"Katherine A Lyseng-Williamson","doi":"10.2165/11202560-000000000-00000","DOIUrl":null,"url":null,"abstract":"<p><p>Oral fixed-dose niacin extended release/simvastatin is associated with clinically relevant improvements in plasma lipid profiles, including lowering of non-high-density lipoprotein cholesterol levels, relative to simvastatin monotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"253-60"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/11202560-000000000-00000","citationCount":"6","resultStr":"{\"title\":\"Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.\",\"authors\":\"Katherine A Lyseng-Williamson\",\"doi\":\"10.2165/11202560-000000000-00000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Oral fixed-dose niacin extended release/simvastatin is associated with clinically relevant improvements in plasma lipid profiles, including lowering of non-high-density lipoprotein cholesterol levels, relative to simvastatin monotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.</p>\",\"PeriodicalId\":11373,\"journal\":{\"name\":\"Drugs in R & D\",\"volume\":\" \",\"pages\":\"253-60\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2165/11202560-000000000-00000\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in R & D\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2165/11202560-000000000-00000\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in R & D","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2165/11202560-000000000-00000","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
Oral fixed-dose niacin extended release/simvastatin is associated with clinically relevant improvements in plasma lipid profiles, including lowering of non-high-density lipoprotein cholesterol levels, relative to simvastatin monotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
